Accordingly, we found that low MELK and ALK mRNA expression is associated with a significantly improved patient RFS rate, depending on whether the patient carries a tumor with the ERα-positive/PR-positive/HER2-negative or the ERα-positive/PR-negative/HER2-positive phenotype, respectively. This evidence concerns the gene MELK and neoplasm.